On December 14, 2019, Pfizer announced 11 BILLION acquisition agreement with Neurocrine Biosciences, Inc. (NBIX) to develop and market first-in-class treatments for epilepsy. Neurocrine Biosciences has an exclusive license to XEN901, a clinical stage selective Nav1.6 sodium channel inhibitor with potential in SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) and other forms of epilepsy, including focal epilepsy.
